A developer of innovative medications for serious central nervous system diseases.
Ongoing Phase I/II Open Label Security Research of Zinc Therapy in ALS Sufferers Currently the clinical investigators at the PNA Center for Neurological Analysis are conducting a Phase I/II open label study of zinc therapy in ALS individuals to determine the protection of zinc in conjunction with low dosages of copper. To date, no safety issues related to zinc therapy have already been seen in the ALS patients. Potential Advantage of Zinc Therapy in ALS Patients The medical investigators at the PNA Center for Neurological Study cite multiple lines of scientific research that suggest a potential advantage of zinc therapy for ALS patients, including: Through the 1950’s, an epidemic of ALS was uncovered on the island of Guam and the Trust Territories of the Pacific that exposed a kind of ALS that was 100 moments more prevalent than in the rest of the world.The next day, an epidemiological study was carried out by trained survey statisticians. The survey contained questions on the overall data of the parents, their places of home, profession, medical history, anthropometric information, age group, tobacco habits, diet and lifestyle during pregnancy, among other factors. Sankaran to receive Rising Star AwardThe study produced at the UGR offers facilitated research into the association of the characteristics of parents, newborn babies and childbirth with contact with pesticides found in the mothers’ placenta. Among the factors associated with an increased existence of pesticides we discover an older age group, higher body mass index, less excess weight gained during pregnancy, lower educational level, higher place of work exposure, first-time motherhood and lower pounds in babies.